Page 10 - Enovo Seeds News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Novo Holdings co-leads Hemab s US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Hemab Raises US$ 55M in Series A Funding
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.
Draupnir Bio strengthens senior management with the appointment of Anna Quattropani as Chief Discovery Officer
as
1
- Draupnir Bio ( Draupnir ), a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, today announces the appointment of Anna Quattropani, PhD, as Chief Discovery Officer (CDO), effective immediately.
Anna brings more than 20 years of experience in drug discovery and development to the role, having established a successful track record in the design of clinical candidates and their development from discovery to the clinic. At Draupnir, Anna will lead internal and external drug discovery and medicinal chemistry efforts in support of Draupnir s growing preclinical pipeline.
Novo Holdings Launches Muna Therapeutics with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases
- Novo Holdings created and built Muna Therapeutics with pioneers in the field of neurodegeneration
- Led by an experienced management team of Entrepreneurs-in-Residence from Novo Seeds
- Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB
News provided by
Share this article
Share this article
COPENHAGEN, Denmark, July 9, 2021 /PRNewswire/ Novo Holdings, a global life science investor, today announces that it has co-led the Series A financing of its portfolio company, Muna Therapeutics ( Muna ), which is pioneering the development of first-in-class small molecule therapeutics for neurodegenerative diseases. The financing also includes Sofinnova Partners, Droia Ventures and LSP Dementia Fund wi